Antibody Information

General Information of This Antibody

Antibody ID	ANI0TYWTR
Antibody Name	Her3-C3
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Her3-C3-ADC-21 (DAR4) [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 24.11% (Day 29)	Low CD276 expression (CD276 +)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	76.37 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Her3-C3-ADC-21 (DAR8) [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 44.00% (Day 15)	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.64% (Day 15)	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546

Her3-C3-ADC-05 (DAR4) [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	32.94 ng/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	65.11 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

References

Ref 1	Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.